Global Information
회사소개 | 문의

고셰병 : 주요 30개국 시장 예측

EPIOMIC EPIDEMIOLOGY SERIES: GAUCHER´S DISEASE FORECAST IN 30 MAJOR MARKETS 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 07월 상품 코드 339844
페이지 정보 영문 120 Pages
가격
US $ 5,800 ₩ 6,617,200 PDF by E-mail (Single User License)
US $ 8,700 ₩ 9,925,800 PDF by E-mail (Site License)
US $ 10,400 ₩ 11,865,300 PDF by E-mail (Global License)


고셰병 : 주요 30개국 시장 예측 EPIOMIC EPIDEMIOLOGY SERIES: GAUCHER´S DISEASE FORECAST IN 30 MAJOR MARKETS 2018-2028
발행일: 2018년 07월 페이지 정보 : 영문 120 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

고셰병(GD)은 GBA 유전자의 선천성·상염색체 열성 변이에 의해 발생하는 질환입니다. GBA 유전자는 글루코세리브로사이다제(glucocerebrosidase, GBA)라는 효소 생산에 관련된 유전자인데, 이 효소가 없으면 glucocerebroside 등의 물질이 마크로파지(macrophages)와 단핵 백혈구(monocytes) 등의 내부에 축적되어 비장·간장·신장·폐 등의 다양한 장기로 전이될 것입니다. 그것들이 독성을 발하는 수준까지 축적되면 다양한 장기와 조직에 악영향을 미치게 됩니다.

세계의 주요 30개국의 고셰병(GAUCHER´S DISEASE) 발증 상황에 대해 분석했으며, 질환 개요와 현재 환자수, 성별·연령 그룹(5세 단위 구분) 발증 상황, 지역별·민족별 동향, 위험인자, 질환 진단과 예후, 주요 증상과 합병증, 향후 동향 전망(향후 10년간) 등의 정보를 정리하여 전해드립니다.

1. 목차

  • 서론
  • 질환의 원인
  • 위험인자와 예방법
  • 질환 진단
  • 지역별/민족별 차이
  • 질환 예후와 임상 경과
  • 주요 합병증 증상과 특징
  • 환자수 정량화 방법
  • 고셰병(GD) 최대 환자수
  • 고셰병 환자의 특징
  • 고셰병 환자의 병존증
  • 약어 리스트
  • 참고 문헌
  • 부록

2. 도표

3. 분석 대상국 리스트

  • 미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 벨기에, 노르웨이, 스웨덴, 핀란드, 덴마크, 오스트리아, 그리스, 루마니아, 슬로베니아, 체코, 리투아니아, 에스토니아, 러시아, 터키, 일본, 중국, 한국, 인도, 브라질, 멕시코, 아르헨티나
LSH 18.07.12

영문목차

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher's Disease in 30 Major Markets

Gaucher's Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage.

This report provides the current prevalent population for GD across 30 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Greece, Romania, Slovenia, Czech Republic, Lithuania, Estonia, Russia, Turkey, Japan, China, South Korea, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the genotypes and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

Splenomegaly

Hepatomegaly

Haematological conditions

Musculoskeletal conditions

Gall stones

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global GD market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on GD prevalent population.

Examination of the prevalence of the different causative gene mutations for GD.

Identify sub-populations within GD which require treatment.

Gain an understanding of the specific markets that have the largest number of GD patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR GAUCHER'S DISEASE
  • FEATURES OF GAUCHER'S DISEASE PATIENTS
  • COMORBIDITIES OF GAUCHER'S DISEASE PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Characteristics of the three types of Gaucher's disease
  • Table 2. Prevalence of Gaucher's disease, total (000s)
  • Table 3. Prevalence of Gaucher's disease, males (000s)
  • Table 4. Prevalence of Gaucher's disease, females (000s)
  • Table 5. Patients with Gaucher's disease by type, total (000s)
  • Table 6. Patients with Gaucher's disease by history of splenectomy, total (000s)
  • Table 7. Patients with type I Gaucher's disease by genotype, total (000s)
  • Table 8. Patients with type I Gaucher's disease by polyneuropathy status, total (000s)
  • Table 9. Patients with type I Gaucher's disease by history of splenectomy, total (000s)
  • Table 10. Patients with type III Gaucher's disease by genotype, total (000s)
  • Table 11. Gaucher's disease patients with thrombocytopaenia, total (000s)
  • Table 12. Gaucher's disease patients with anaemia, total (000s)
  • Table 13. Gaucher's disease patients with bleeding tendencies, total (000s)
  • Table 14. Gaucher's disease patients with bone/joint pain, total (000s)
  • Table 15. Gaucher's disease patients with radiological bone disease, total (000s)
  • Table 16. Gaucher's disease patients with bone crisis, total (000s)
  • Table 17. Type I Gaucher's disease patients with gallstones, total (000s)
  • Table 18. Type I Gaucher's disease patients with thrombocytopaenia, total (000s)
  • Table 19. Type I Gaucher's disease patients with anaemia, total (000s)
  • Table 20. Type I Gaucher's disease patients with bleeding tendencies, total (000s)
  • Table 21. Type I Gaucher's disease patients with bone crisis, total (000s)
  • Table 22. Type I Gaucher's disease patients with radiological bone disease, total (000s)
  • Table 23. Type I Gaucher's disease patients with Erlenmeyer flask deformity, total (000s)
  • Table 24. Type I Gaucher's disease patients with osteopaenia, total (000s)
  • Table 25. Type I Gaucher's disease patients with marrow infiltration, total (000s)
  • Table 26. Type I Gaucher's disease patients with bone infarct, total (000s)
  • Table 27. Type I Gaucher's disease patients with avascular necrosis, total (000s)
  • Table 28. Type I Gaucher's disease patients with a history of fracture, total (000s)
  • Table 29. Type I Gaucher's disease patients with lytic lesions, total (000s)
  • Table 30. Type I Gaucher's disease patients with Parkinson's disease, total (000s)
  • Table 31. Abbreviations and acronyms used in the report
  • Table 32. USA prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 33. USA prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 34. Canada prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 35. Canada prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 36. France prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 37. France prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 38. Germany prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 39. Germany prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 40. Italy prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 41. Italy prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 42. Spain prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 43. Spain prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 44. UK prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 45. UK prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 46. Poland prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 47. Poland prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 48. Netherlands prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 49. Netherlands prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 50. Belgium prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 51. Belgium prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 52. Norway prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 53. Norway prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 54. Sweden prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 55. Sweden prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 56. Finland prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 57. Finland prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 58. Denmark prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 59. Denmark prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 60. Austria prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 61. Austria prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 62. Greece prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 63. Greece prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 64. Romania prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 65. Romania prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 66. Slovenia prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 67. Slovenia prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 68. Czech Republic prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 69. Czech Republic prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 70. Lithuania prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 71. Lithuania prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 72. Estonia prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 73. Estonia prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 74. Russia prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 75. Russia prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 76. Turkey prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 77. Turkey prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 78. Japan prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 79. Japan prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 80. China prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 81. China prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 82. South Korea prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 83. South Korea prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 84. India prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 85. India prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 86. Brazil prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 87. Brazil prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 88. Mexico prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 89. Mexico prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Table 90. Argentina prevalence of Gaucher's disease by 5-yr age cohort, males (000s)
  • Table 91. Argentina prevalence of Gaucher's disease by 5-yr age cohort, females (000s)
  • Figure 1. Incidence of type I Gaucher's disease by age
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research